March.27.2015
Orrick, Herrington & Sutcliffe (Europe) LLP represented Shore Capital as nominated adviser and broker to RedX Pharma on its initial public offering on London’s Alternative Investment Market (AIM).
RedX has raised £15 million and is valued at about £55.2 million on admission. It is a drug development company formed in 2010 that is focused on improving the characteristics of drugs in the areas of cancer and infectious disease.
Orrick’s team was led by Corporate partner Hilary Winter and comprised Nell Scott, Katie Cotton and David Griffiths.